Williams Jones & Associates’s Aratana Therapeutics, Inc. PETX Stock Holding History

Williams Jones & Associates’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,345	Closed	-$37K	–	428
2019 Q1	$37K	Buy	10,345 +300	+3%	+$1.3K	﹤0.01%	405
2018 Q4	$62K	Sell	10,045 -7,000	-41%	-$42.7K	﹤0.01%	381
2018 Q3	$100K	Sell	17,045 -2,000	-11%	-$9.99K	﹤0.01%	430
2018 Q2	$81K	Sell	19,045 -12,475	-40%	-$62.9K	﹤0.01%	427
2018 Q1	$139K	Sell	31,520 -19,700	-38%	-$87.9K	﹤0.01%	418
2017 Q4	$269K	Sell	51,220 -86,455	-63%	-$529K	0.01%	376
2017 Q3	$844K	Buy	137,675 +23,300	+20%	+$147K	0.02%	238
2017 Q2	$827K	Buy	+114,375	New	+$703K	0.02%	240

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Williams Jones & Associates's PETX Position: Q2 2019 in Review

Williams Jones & Associates sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 10,345 shares — an estimated $37K sold.

Williams Jones & Associates first reported a position in PETX in Q2 2017 and held it in 8 quarters. The position peaked at $844K in Q3 2017. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

Williams Jones & Associates reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Williams Jones & Associates sold 10,345 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $37K.
Williams Jones & Associates first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 8 quarters.
Williams Jones & Associates's Aratana Therapeutics, Inc. position peaked at $844K in Q3 2017.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Williams Jones & Associates's 13F filing for Q2 2019, filed 14 Aug 2019.